Screening and characterization of inhibitory vNAR targeting nanodisc-assembled influenza M2 proteins

Yu, Chuandi; Ding, Wen; Zhu, Lei; Zhou, Yuhang; Dong, Yingkui; Li, Ling; Liu, Juanjuan; Wang, Yizhuo; Li, Zehua; Zhu, Lingkai; Fajun, Chen; Ruan, Meiling; Qian, Dongming; Wang, Yujuan; Wu, Bo; Han, Xu; Li, Ming; Bi, Yunchen; Wang, Hao; Wang, Weiqian; Peng, Chao; Xing, Lei; Shen, Bing; Dai, Hang; Zha, Lisha; Zhao, Hongxin; Wang, Junfeng

doi:10.1016/j.isci.2022.105736

Cited by 7 publications

(3 citation statements)

References 79 publications

(107 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of strong and rapid IgNAR recall was also observed when undergoing a response following a re-encounter with antigens. Many biological explorations on bamboo sharks, which serve as a promising small animal model for high-affinity sdAb generation, have been conducted [ 26 , 35 , 55 , 56 , 57 ].…”

Section: Structural Characteristics and Advantages Of Ignarmentioning

confidence: 99%

Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies?

Jiang,

Sun,

et al. 2023

Marine Drugs

View full text Add to dashboard Cite

Antibodies represent a relatively mature detection means and serve as therapeutic drug carriers in the clinical diagnosis and treatment of cancer—among which monoclonal antibodies (mAbs) currently occupy a dominant position. However, the emergence and development of small-molecule monodomain antibodies are inevitable due to the many limitations of mAbs, such as their large size, complex structure, and sensitivity to extreme temperature, and tumor microenvironments. Thus, since first discovered in Chondroid fish in 1995, IgNAR has become an alternative therapeutic strategy through which to replace monoclonal antibodies, thus entailing that this novel type of immunoglobulin has received wide attention with respect to clinical diagnoses and tumor therapies. The variable new antigen receptor (VNAR) of IgNAR provides an advantage for the development of new antitumor drugs due to its small size, high stability, high affinity, as well as other structural and functional characteristics. In that respect, a better understanding of the unique characteristics and therapeutic potential of IgNAR/VNAR in clinical and anti-tumor treatment is needed. This article reviews the advantages of its unique biochemical conditions and molecular structure for clinical diagnoses and novel anti-tumor drugs. At the same time, the main advantages of the existing conjugated drugs, which are based on single-domain antibodies, are introduced here, thereby providing new ideas and methods for the development of clinical diagnoses and anti-tumor therapies in the future.

show abstract

Section: Structural Characteristics and Advantages Of Ignarmentioning

confidence: 99%

Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies?

Jiang,

Sun,

et al. 2023

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…They subsequently solved the complex structure of APJ-JN241 through crystallography and designed a new nanobody, JN241-9 APJ, capable of antagonizing APJ for the treatment of chronic heart failure. Similarly, Yu et al isolated nanobodies targeting the influenza matrix-2 (M2) protein, a tetrameric transmembrane proton channel important for virus uncoating in endosomes [43]. M2-nanodiscs were used in both the immunization of Chiloscyllium plagiosum (a shark) and as the target for panning of the phage-displayed immune library.…”

Section: Nanodiscsmentioning

confidence: 99%

Methods for Engineering Binders to Multi-Pass Membrane Proteins

Thomas,

Chockalingam,

Chen

2023

Bioengineering

View full text Add to dashboard Cite

Numerous potential drug targets, including G-protein-coupled receptors and ion channel proteins, reside on the cell surface as multi-pass membrane proteins. Unfortunately, despite advances in engineering technologies, engineering biologics against multi-pass membrane proteins remains a formidable task. In this review, we focus on the different methods used to prepare/present multi-pass transmembrane proteins for engineering target-specific biologics such as antibodies, nanobodies and synthetic scaffold proteins. The engineered biologics exhibit high specificity and affinity, and have broad applications as therapeutics, probes for cell staining and chaperones for promoting protein crystallization. We primarily cover publications on this topic from the past 10 years, with a focus on the different formats of multi-pass transmembrane proteins. Finally, the remaining challenges facing this field and new technologies developed to overcome a number of obstacles are discussed.

show abstract

“…[41] In this case, the coupling reaction of CO 2 and NO x − may not only achieve highly efficient urea production, but also reduce the carbon footprint and purify the polluted water. [42] Unfortunately, urea production by co-reducing CO 2 and NO x − is facing challenges of complex product distribution, multistep proton-coupling electron-transfer process, and ambiguous C-N coupling mechanism. In this regard, no matter what nitrogen source is, high-performance electrocatalyst is the prerequisite for the realization of C-N coupling, which should fulfill the following requirements: 1) adequate adsorption and activation of CO 2 and nitrogen species; 2) optimized adsorption energy of key intermediate species; 3) sufficient active sites for simultaneously reducing various reactants; 4) thermodynamically and kinetically feasible C-N coupling process; and 5) effective suppression of undesired side reactions.…”

Section: Introductionmentioning

confidence: 99%

Fundamentals and Rational Design of Heterogeneous C‐N Coupling Electrocatalysts for Urea Synthesis at Ambient Conditions

Wan,

Zheng,

Yan

et al. 2024

Advanced Energy Materials

View full text Add to dashboard Cite

Electrocatalytic C‐N coupling reaction is regarded as a promising strategy for achieving clean and sustainable urea production by coreducing CO2 and nitrogen species, thus contributing to carbon neutrality and the artificial nitrogen cycle. However, restricted by the sluggish adsorption of reactants, competitive side reactions, and multistep reaction pathways, the electrochemical urea production suffers from a low urea yield rate and low selectivity so far. In order to comprehensively improve urea synthesis performance, it is crucial to develop highly efficient catalysts for electrochemical C‐N coupling. In this article, the catalyst‐designing strategies, C‐N coupling mechanisms, and fundamental research methods are reviewed. For the coreduction of CO2 and different nitrogen species, several prevailing reaction mechanisms are discussed. With the aim of establishing the standard research system, the fundamentals of electrocatalytic urea synthesis research are introduced. The most important catalyst‐designing strategies for boosting the electrocatalytic urea production are discussed, including heteroatom doping, vacancy engineering, crystal facet regulation, atom‐scale modulation, alloying and heterostructure construction. Finally, the challenges and perspectives are proposed for future industrial applications of electrochemical urea production by C‐N coupling.

show abstract

Screening and characterization of inhibitory vNAR targeting nanodisc-assembled influenza M2 proteins

Cited by 7 publications

References 79 publications

Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies?

Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies?

Methods for Engineering Binders to Multi-Pass Membrane Proteins

Fundamentals and Rational Design of Heterogeneous C‐N Coupling Electrocatalysts for Urea Synthesis at Ambient Conditions

Contact Info

Product

Resources

About